[Successful therapy with cyclosporine in a case with interstitial pneumonitis associated with polymyositis]. 1996

T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
First Department of Internal Medicine, Yokohama City University School of Medicine.

We describe a case of interstitial pneumonitis associated with polymyositis who responded well to cyclosporine therapy. In October, 1993, a 49-year-old female was admitted to our hospital because of fever, muscle weakness and progressive dyspnea. Interstitial pneumonitis with polymyositis was diagnosed and daily oral steroid therapy was started. As the therapy was ineffective, pulse intravenous steroid therapies followed by oral cyclophosphamide and steroid therapy was given. Whereas serum levels of muscle enzymes decreased, she became progressively hypoxemic. No effect was observed in series of therapy including additional pulse steroid therapy, pulse intravenous cyclophosphamide therapy, oral azathioprine and oral bethametazone therapy. In April, 1994, oral cyclosporine was started. After daily oral cyclosporine was combined with steroid, her symptoms, chest X-ray, chest CT and pulmonary function tests significantly improved. Her disease became stable and there was no signs of recurrence since then. It is suggested that cyclosporine is useful for the treatment of progressive interstitial pneumonitis associated with polymyositis.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D017285 Polymyositis Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9) Myositis, Multiple,Polymyositis Ossificans,Polymyositis, Idiopathic,Idiopathic Polymyositides,Idiopathic Polymyositis,Multiple Myositis,Myositides, Multiple,Ossificans, Polymyositis,Polymyositides,Polymyositides, Idiopathic
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial

Related Publications

T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
February 1995, Ryumachi. [Rheumatism],
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
January 1998, Internal medicine (Tokyo, Japan),
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
October 1987, The Journal of rheumatology,
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
July 1999, The Journal of rheumatology,
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
October 1992, Nihon Kyobu Shikkan Gakkai zasshi,
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
January 2006, Modern rheumatology,
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
January 2024, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
August 1989, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
December 1991, The Journal of pediatrics,
T Soga, and E Hagiwara, and A Shirai, and T Igarashi, and Y Ishigatsubo, and T Okubo
April 1974, Chest,
Copied contents to your clipboard!